Landin-Olsson M - Search Results

1

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.

Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D. Ahrén B, et al. Diabetes Care. 2002 May;25(5):869-75. doi: 10.2337/diacare.25.5.869. Diabetes Care. 2002. PMID: 11978683 Clinical Trial.

2

Islet cell and thyrogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the diabetes incidence study in Sweden.

Landin-Olsson M, Karlsson FA, Lernmark A, Sundkvist G. Landin-Olsson M, et al. Diabetes. 1992 Aug;41(8):1022-7. doi: 10.2337/diab.41.8.1022. Diabetes. 1992. PMID: 1628762

3

Glutamate decarboxylase antibody levels predict rate of beta-cell decline in adult-onset diabetes.

Gottsäter A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G, Hagopian WA. Gottsäter A, et al. Diabetes Res Clin Pract. 1995 Feb;27(2):133-40. doi: 10.1016/0168-8227(95)01026-a. Diabetes Res Clin Pract. 1995. PMID: 7607051

4

Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients.

Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Gottsäter A, et al. Diabetes Care. 1993 Jun;16(6):902-10. doi: 10.2337/diacare.16.6.902. Diabetes Care. 1993. PMID: 8325204

5

Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes.

Littorin B, Sundkvist G, Hagopian W, Landin-Olsson M, Lernmark A, Ostman J, Arnqvist HJ, Blohmé G, Bolinder J, Eriksson JW, Lithner F, Scherstén B, Wibell L. Littorin B, et al. Diabetes Care. 1999 Mar;22(3):409-12. doi: 10.2337/diacare.22.3.409. Diabetes Care. 1999. PMID: 10097919

6

Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds.

Törn C, Landin-Olsson M, Ostman J, Scherstén B, Arnqvist H, Blohmé G, Björk E, Bolinder J, Eriksson J, Littorin B, Nyström L, Sundkvist G, Lernmark A. Törn C, et al. Diabetes Metab Res Rev. 2000 Nov-Dec;16(6):442-47. doi: 10.1002/1520-7560(2000)9999:9999<::aid-dmrr152>3.0.co;2-t. Diabetes Metab Res Rev. 2000. PMID: 11114103

7

Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage.

Törn C, Landin-Olsson M, Lernmark A, Scherstén B, Ostman J, Arnqvist HJ, Björk E, Blohmé G, Bolinder J, Eriksson J, Littorin B, Nyström L, Sundkvist G. Törn C, et al. Autoimmunity. 2001;33(2):115-20. doi: 10.3109/08916930108995996. Autoimmunity. 2001. PMID: 11264790

8

Family characteristics and life events before the onset of autoimmune type 1 diabetes in young adults: a nationwide study.

Littorin B, Sundkvist G, Nyström L, Carlson A, Landin-Olsson M, Ostman J, Arnqvist HJ, Björk E, Blohmé G, Bolinder J, Eriksson JW, Scherstén B, Wibell L; Diabetes Incidence Study in Sweden (DISS). Littorin B, et al. Diabetes Care. 2001 Jun;24(6):1033-7. doi: 10.2337/diacare.24.6.1033. Diabetes Care. 2001. PMID: 11375366

9

Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in Type 1 diabetes.

Schölin A, Törn C, Nyström L, Berne C, Arnqvist H, Blohmé G, Bolinder J, Eriksson JW, Kockum I, Landin-Olsson M, Ostman J, Karlsson FA, Sundkvist G, Björk E. Schölin A, et al. Diabet Med. 2004 May;21(5):447-55. doi: 10.1111/j.1464-5491.2004.01175.x. Diabet Med. 2004. PMID: 15089789

10

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Home P, et al. Diabetes Care. 2004 May;27(5):1081-7. doi: 10.2337/diacare.27.5.1081. Diabetes Care. 2004. PMID: 15111525 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

199 results

Search Page